Log In
BCIQ
Print this Print this
 

Virexxa

  Manage Alerts
Collapse Summary General Information
Company Pharmsynthez JSC
DescriptionProgesterone receptor agonist
Molecular Target Progesterone receptor (PGR)
Mechanism of ActionProgesterone receptor antagonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationEndometrial cancer
Indication DetailsTreat advanced and relapsed hormone-resistant endometrial cancer
Regulatory Designation U.S. - Orphan Drug (Treat advanced and relapsed hormone-resistant endometrial cancer)
PartnerXenetic Biosciences Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$93.7M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/16/2015

$93.7M

0

0

Get a free BioCentury trial today